1,200 karma · joined July 23, 2021
To anyone interested in this topic I highly recommend exploring the literature connecting RA, glucose metabolism abnormalities, and the benefits of fasting/dietary changes.
[1] Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review
[1] Airborne transmission of respiratory viruses https://www.science.org/lookup/doi/10.1126/science.abd9149
[2] Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks https://pubs.acs.org/doi/10.1021/acsnano.0c03252#
However, vaccination induces a slightly different immune response compared to natural infection [2][3] . These differences may account for variation in effectiveness between vaccine-induced and naturally acquired immunity.
[1] Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination https://www.cell.com/immunity/fulltext/S1074-7613(21)00308-3
[2] Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection https://pubmed.ncbi.nlm.nih.gov/34103407/
[3] mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition https://www.medrxiv.org/content/medrxiv/early/2021/04/07/202...
Still, the benefits of vaccination remain significant - vaccines are helping prevent severe outcomes like hospitalization and death for many people.
Researching formulations that are more robust to viral resistance is already becoming a top priority. Diversifying viral elimination strategies at the population level will also be critical. Mandatory nonpharmaceutical interventions such as lock-downs and masking may help slow the spread of the virus, but at this point those measures will not stop the spread, because SARS-CoV-2 is highly contagious and primarily transmitted through the air (as acknowledged by the WHO and CDC) [3].
[1] Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e4.htm
[2] Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce https://www.nejm.org/doi/full/10.1056/NEJMc2112981
[3] Airborne transmission of respiratory viruses https://www.science.org/lookup/doi/10.1126/science.abd9149
[1] Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial https://pubmed.ncbi.nlm.nih.gov/33983065/
[2] Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19 https://www.frontiersin.org/articles/10.3389/fphar.2021.6526...
[3] Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 https://pubmed.ncbi.nlm.nih.gov/33306283/
[4] Remdesivir for the Treatment of Covid-19 - Final Report https://pubmed.ncbi.nlm.nih.gov/32445440/
I accurately transcribed facts from an official CDC document, and even linked the source, nothing more. Do you really think that is fear-mongering?
The CDC is actively investigating many of the reports, dismissing them as not confirmed is a bit disingenuous at the very least.
> Representing 13 universities, cardiovascular testing was performed in 1597 athletes (964 men [60.4%]). Thirty-seven (including 27 men) were diagnosed with COVID-19 myocarditis (overall 2.3%; range per program, 0%-7.6%); 9 had clinical myocarditis and 28 had subclinical myocarditis. If cardiac testing was based on cardiac symptoms alone, only 5 athletes would have been detected (detected prevalence, 0.31%). Cardiac magnetic resonance imaging for all athletes yielded a 7.4-fold increase in detection of myocarditis (clinical and subclinical). Follow-up CMR imaging performed in 27 (73.0%) demonstrated resolution of T2 elevation in all (100%) and late gadolinium enhancement in 11 (40.7%).
[1] Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection https://jamanetwork.com/journals/jamacardiology/fullarticle/...
Here are a couple more good papers I skimmed through today while looking into this topic. I agree on the "not likely to immediately kill a bunch of people" point. From what I can tell, there are very few longitudinal studies evaluating the health outcomes from metallic corrosion and wear from implants.
Citing [1], stainless steel corrosion is associated with "distinct inflammation and tissue reactions in the surrounding soft tissue with high amounts of particles".
[1] Wear and corrosion in medical applications https://www.degruyter.com/document/doi/10.1515/cdbme-2020-31...
[2] Difference in metallic wear distribution released from commercially pure titanium compared with stainless steel plates https://link.springer.com/article/10.1007/s00402-003-0614-9
For males age 16-17 the reporting rate of myopericarditis after 2 doses of Pfizer is 71.5 per 1 million doses administered (0.0071%) [1].
For males aged 18-24 the reporting rate after 2 doses of Pfizer or Moderna is ~37 per 1 million doses (0.0037%).
[1] https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-...
Are there longitudinal studies proving that these particles do not pose a health risk?
> So likely nothing to worry about at scale
> About 500,000 people have received shots from the three suspended Moderna batches
Why are you so confidently advocating for a "safe until proven unsafe" mentality here? The health impacts from this contamination are completely unknown, and could impact a lot of people, and their children, etc.
EDIT: down vote all you want, armchair reasoning does not prove that this contamination is safe - cite some relevant scientific literature to support your claims
This is not true, according to the CDC (as of August 18th) there at least 742 cases of myocarditis and myopericarditis associated with vaccination, potentially upwards of ~1,300 [1].
For males age 16-17 the reporting rate of myopericarditis after 2 doses of Pfizer is 71.5 per 1 million doses administered (0.0071%) [1].
Compared to natural infection, vaccination is likely still a favorable tradeoff for most people. However the tradeoffs are highly dependent on age, health, and gender. Stratifying by these factors is essential for any scientifically accurate discussion of risks.
[1] https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-...
All of those medications can be prescribed prophylactically (early in the symptomatic phase) by just about any clinic.
I'm not advocating against vaccination, just pointing out that early treatment with widely available and existing medicines has also proven to be effective in reducing severe outcomes.
This is not true. Since the beginning of the pandemic front line doctors have been successfully reducing hospitalization and death through early treatment with antivirals, corticosteriods, and antithrombotics.
[1] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...
[2] Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.1...
[3] Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection https://rcm.imrpress.com/EN/article/downloadArticleFile.do?a...
[4] Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents https://www.sciencedirect.com/science/article/abs/pii/S03069...
[5] Multidrug treatment for COVID-19 https://www.jstage.jst.go.jp/article/ddt/advpub/0/advpub_202...
The proposed hash based encoding function is not differentiable, so it doesn’t appear this method can be used for training at all.
I’m not aware of any hash functions that are analytically differentiable, so to support efficient back-propagation I suspect that some fundamental changes to this method would be necessary.
Apparently some people here find that to be disagreeable? I would love to hear their perspective and reasoning.
Your chances of survival and healthy recovery greatly increase if you begin treatment early in the symptomatic phase with antivirals, corticosteroids, and antithrombotics.
Mistake number 1 is having severe symptoms and waiting for days before seeking treatment. Most people are seemingly unaware of this advice, but many front line doctors have been using these techniques to significantly reduce hospitalization and death since the beginning of the pandemic.
[1] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...
[2] Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.1...
[3] Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection
https://rcm.imrpress.com/EN/article/downloadArticleFile.do?a...
[4] Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents
https://www.sciencedirect.com/science/article/abs/pii/S03069...
> Moreover, recent epidemiology suggests that melatonin usage may reduce the risk for contracting COVID-19. A recent retrospective study, examining data from 26 799 subjects in a COVID-19 registry and using propensity score matching to account for a range of covariates, found that current supplementation with melatonin was associated with a significant 28% reduction in risk for serologically detectible COVID-19 infection. Among Black Americans, this reduction in risk was a remarkable 52% (OR=0.48, 95% CI 0.31 to 0.75).
> More generally, it might be feasible to define a simple nutraceutical regimen that could reduce the risk for COVID-19 and a range of other viral infections. There is growing evidence, both case–control and ecologic, that replete vitamin D status not only markedly improves the clinical course of COVID-19, but also is associated with decreased risk for clinically detectible infection.
> COVID-19 epidemiology also suggests that higher zinc status is associated with both a better clinical course in this disorder and lower risk for infection.42 43 Especially in the elderly, who are more prone to poor zinc status, zinc supplementation has been found to boost acquired, antigen-specific immunity, while also exerting an anti-inflammatory action; such supplementation of the elderly was associated with a marked decrease in total infections in a 12-month randomised controlled trial.
> Hence, it is not unreasonable to suggest that a supplementation programme incorporating vitamin D, zinc, melatonin and possibly additional nutraceuticals could reduce risk for and aid control of COVID-19 and a range of other viral infections.
This is yet another paper contributing to a growing body of evidence suggesting that collectively and scientifically we do not deeply understand the higher order consequences of mandatory interventions such as lock-downs, school/work/daycare closures, social distancing, etc.
These effects are crucial to understand because they govern the tradeoff between benefits and consequences, which is the central concern of all public health policy.
> In SARS-CoV-2 we find evidence for common intra-host purifying selection against nonsense, missense and synonymous mutations, such that the true underlying mutation rate is about 50% higher than would be estimated if one assumes that the mutation rate is the rate of appearance of mutations in the circulating population. This has implications for methods to determine mutation rates, for determining times to common ancestry and the potential for vaccine escape.
> The most potently neutralizing antibodies to SARS-CoV-2 — including those in clinical use and dominant in polyclonal sera — target the spike RBD. Mutations in the RBD that reduce binding by antibodies have emerged among SARS-CoV-2 variants, highlighting the need for antibodies and vaccines that are robust to viral escape.
> we identify neutralizing antibodies with exceptional sarbecovirus breadth and a corresponding resistance to SARS-CoV-2 escape. One of these antibodies, S2H97, binds with high affinity across all sarbecovirus clades to a cryptic epitope and prophylactically protects hamsters from viral challenge.
> S2H97 exhibits notably tight binding to all RBDs tested, making it, to our knowledge, the broadest pan-sarbecovirus RBD antibody described to date.
> We cannot predict which mutations will next rise to prominence as SARS-CoV-2 continues to evolve, but it seems likely that they will include additional RBM mutations that affect recognition by infection- and vaccine-elicited antibodies.
This complements a growing body of promising research that will lead to next generation vaccines which should be more resistant to viral evolution. Such research is vital because the current mRNA vaccines induce an immune response that is highly targeted toward the spike protein RBD. Nearly every variant of concern has acquired at least one mutation which confers a degree of immune escape from antibodies targeting the S protein RBD.
[1] SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape https://www.nature.com/articles/s41586-021-03807-6
I agree though, the search space can explode quickly. Assuming Ivermectin is useless might be fair given the lackluster benefits seen in RCTs using it in single-drug regime. P95 is 2 sigma - typically in RCTs you'd be looking for stronger statistical significance, to reduce the risk of false positives as you allude to.
You certainly have a valid point, but hopefully you agree that it doesn't need to stop us from continuing to evaluate treatments using existing and widely available medicines.